Enzo Biochem, Inc.
ENZB
$0.4899
-$0.0001-0.02%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.25% | -20.41% | -16.00% | 7.17% | 13.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.25% | -20.41% | -16.00% | 7.17% | 13.83% |
| Cost of Revenue | -18.02% | -9.61% | -25.94% | -4.18% | -6.22% |
| Gross Profit | -10.39% | -34.01% | 2.38% | 24.06% | 45.76% |
| SG&A Expenses | -15.80% | -33.93% | -42.38% | -50.64% | -7.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.78% | -25.95% | -36.98% | -36.45% | -10.95% |
| Operating Income | 26.68% | 33.86% | 63.04% | 75.54% | 51.93% |
| Income Before Tax | -44.61% | 45.89% | 87.07% | 73.02% | 70.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.61% | 45.89% | 87.07% | 73.02% | 70.16% |
| Earnings from Discontinued Operations | 86.94% | 67.59% | -118.45% | 87.81% | 73.92% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.85% | 48.97% | -123.30% | 80.11% | 72.96% |
| EBIT | 26.68% | 33.86% | 63.04% | 75.54% | 51.93% |
| EBITDA | 33.06% | 36.55% | 65.68% | 77.86% | 51.06% |
| EPS Basic | 51.49% | 50.99% | -122.32% | 80.81% | 73.91% |
| Normalized Basic EPS | -39.25% | 48.09% | 87.95% | 73.97% | 71.16% |
| EPS Diluted | 51.49% | 46.89% | -122.34% | 80.81% | 73.91% |
| Normalized Diluted EPS | -39.25% | 48.09% | 87.95% | 73.97% | 71.16% |
| Average Basic Shares Outstanding | 3.58% | 4.10% | 3.54% | 3.71% | 3.61% |
| Average Diluted Shares Outstanding | 3.58% | 4.10% | 3.54% | 3.71% | 3.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |